Immune Checkpoint Inhibition in Metastatic Urothelial Cancer

Tom Powles; Kate Smith; Arnulf Stenzl; Jens Bedke

doi:10.1016/j.eururo.2017.03.047

Immune Checkpoint Inhibition in Metastatic Urothelial Cancer

Eur Urol. 2017 Oct;72(4):477-481. doi: 10.1016/j.eururo.2017.03.047. Epub 2017 Apr 14.

Authors

Tom Powles¹, Kate Smith², Arnulf Stenzl³, Jens Bedke⁴

Affiliations

¹ Barts Cancer Institute, London, UK. Electronic address: thomas.powles@bartshealth.nhs.uk.
² Barts Cancer Institute, London, UK.
³ Department of Urology, University of Tübingen, Tübingen, Germany.
⁴ Department of Urology, University of Tübingen, Tübingen, Germany. Electronic address: jens.bedke@med.uni-tuiebingen.de.

PMID: 28413128
DOI: 10.1016/j.eururo.2017.03.047

Abstract

Immune checkpoint inhibitors are a new treatment option in metastatic urothelial cancer on the basis of available phase 2 and 3 trials. Predictive biomarkers are needed. These should go beyond PD-L1 expression, which is showing inconsistent results across trials.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Biomarkers, Tumor / metabolism
Chemotherapy, Adjuvant
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Disease Progression
Disease-Free Survival
Humans
Neoadjuvant Therapy
Neoplasm Metastasis
Randomized Controlled Trials as Topic
Signal Transduction / drug effects*
Time Factors
Treatment Outcome
Urologic Neoplasms / drug therapy*
Urologic Neoplasms / immunology
Urologic Neoplasms / mortality
Urologic Neoplasms / pathology
Urothelium / drug effects*
Urothelium / immunology
Urothelium / pathology

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor